GELNIQUE 3%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GELNIQUE 3% (GELNIQUE 3%).
Oxybutynin is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3 subtypes), primarily M3 receptors, leading to relaxation of detrusor smooth muscle and inhibition of involuntary bladder contractions.
| Metabolism | Primarily metabolized by cytochrome P450 enzymes, specifically CYP3A4, to active and inactive metabolites (e.g., desethyloxybutynin). |
| Excretion | Renal: 70% as unchanged drug; fecal: 20% as metabolites; biliary: 10% |
| Half-life | Terminal half-life: 7.5 hours (range 5-10 h); clinically, steady-state achieved in 2 days |
| Protein binding | 97% bound to alpha-1-acid glycoprotein and albumin |
| Volume of Distribution | Vd: 2.9 L/kg (range 2.0-4.0), indicating extensive tissue distribution |
| Bioavailability | Topical: 18% (range 10-30%) relative to intravenous dose |
| Onset of Action | Topical: 2-4 hours for first measurable anticholinergic effect; maximal effect by 8-12 weeks |
| Duration of Action | Duration: 24 hours with once-daily application; clinical effect maintained with regular use |
Apply 1 gram (4 metered actuations) of gel topically to dry intact skin on abdomen, upper thighs, or upper arms once daily.
| Dosage form | GEL, METERED |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²); use caution. |
| Liver impairment | No specific dose adjustment; contraindicated in Child-Pugh Class C (severe hepatic impairment). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; monitor for anticholinergic effects and cognitive impairment in elderly patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GELNIQUE 3% (GELNIQUE 3%).
| Breastfeeding | Oxybutynin is excreted into human milk in small amounts. The milk-to-plasma (M/P) ratio is not established. Due to potential for anticholinergic effects in the nursing infant (e.g., dry mouth, constipation, urinary retention), caution is advised. Consider alternative therapies, especially in neonates or preterm infants. |
| Teratogenic Risk | GELNIQUE 3% (oxybutynin topical gel) is classified as Pregnancy Category B. Animal studies have not demonstrated fetal risk, but there are no adequate and well-controlled studies in pregnant women. Oxybutynin crosses the placenta. First trimester: No known teratogenic effects, but data limited. Second and third trimesters: Potential for anticholinergic effects on fetal heart rate and gastrointestinal motility; use only if clearly needed. |
■ FDA Black Box Warning
Not applicable (no black box warning for oxybutynin topical gel).
| Serious Effects |
["Urinary retention","Gastric retention","Uncontrolled narrow-angle glaucoma","Known hypersensitivity to oxybutynin or any ingredient"]
| Precautions | ["Angioedema (rare but serious hypersensitivity reaction)","Urinary retention (may precipitate in patients with bladder outlet obstruction)","Gastrointestinal obstructive disorders (risk of delayed gastric emptying)","Controlled narrow-angle glaucoma (may exacerbate)","Central nervous system effects (e.g., somnolence, dizziness; caution with activity requiring alertness)","Dermatitis at application site"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate and blood pressure due to anticholinergic effects. Fetal monitoring: Consider non-stress test or biophysical profile if prolonged use in third trimester. Assess for maternal urinary retention, constipation, and heat intolerance (reduced sweating). |
| Fertility Effects | Oxybutynin may affect male and female fertility due to anticholinergic effects on sexual function (e.g., erectile dysfunction, decreased libido). Animal studies show no direct impairment of fertility, but clinical significance in humans is uncertain. Reversible upon discontinuation. |